<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC4865845/results/search/funders/results.xml">
  <result pre="of Molecular BiologyGermany[2], Steinbeis Innovation gGmbH, Center for Systems BiomedicineGermany[3]," exact="Institut Pasteur," post="Biology of Infection UnitFrance[4], Inserm U1117France[5], Institute of Technology,"/>
  <result pre="3; Supplementary Methods). Of these, 20 compounds—8 of them already" exact="Food and Drug Administration" post="approved—interacting with six distinct proviral factors or pathways (Table"/>
  <result pre="or in combination. Since some of the drugs are already" exact="Food and Drug Administration" post="approved for other diseases, this has the potential to"/>
  <result pre="were &amp;gt;98% pure for GFP expression. The IAV/WSN/1933(H1N1) (provided by" exact="St. Jude Children's Research Hospital," post="USA) was produced by reverse genetics as described42, subsequently"/>
  <result pre="conducted according to project #2014-0019, which was approved by the" exact="Institut Pasteur" post="Animal Ethics Committee on 17 October 2014. Two different"/>
  <result pre="USA, and CHIKV-GFP a kind gift from Dr Steve Higgs," exact="Kansas State University," post="KS, USA. pcDNA3.1-VEGFR-3 and pcDNA3.1-VEGFR-3-G857R were kindly provided by"/>
  <result pre="the EU project FP7-ICRES (grant no. 261202), and LabEx IBEID," exact="Institut Pasteur" post="and Inserm. S.B. was funded by the Pasteur-Roux fellowship."/>
 </snippets>
</snippetsTree>
